First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy.
作者信息
VandenDriessche Thierry, Pipe Steven W, Pierce Glenn F, Kaczmarek Radoslaw
机构信息
Department of Gene Therapy & Regenerative Medicine, Vrije Universiteit Brussel, Brussels, Belgium; Center for Molecular & Vascular Biology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA.
出版信息
Mol Ther. 2022 Nov 2;30(11):3335-3336. doi: 10.1016/j.ymthe.2022.09.020. Epub 2022 Oct 19.
Abstract
摘要
相似文献
1
First conditional marketing authorization approval in the European Union for hemophilia "A" gene therapy.血友病“A”基因疗法首次获得欧盟有条件上市许可批准。
Mol Ther. 2022 Nov 2;30(11):3335-3336. doi: 10.1016/j.ymthe.2022.09.020. Epub 2022 Oct 19.
2
Use of the conditional marketing authorization pathway for oncology medicines in Europe.欧洲肿瘤药物有条件上市许可途径的使用情况。
Clin Pharmacol Ther. 2015 Nov;98(5):534-41. doi: 10.1002/cpt.174. Epub 2015 Jul 17.
3
Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.2007 年至 2021 年美国和欧洲加速批准或有条件上市药物的治疗价值。
JAMA Health Forum. 2022 Aug 5;3(8):e222685. doi: 10.1001/jamahealthforum.2022.2685.
4
ADA-SCID Gene Therapy Endorsed By European Medicines Agency For Marketing Authorization.欧洲药品管理局批准腺苷脱氨酶严重联合免疫缺陷症基因疗法进行上市许可。
Mol Ther. 2016 Jun;24(6):1013-1014. doi: 10.1038/mt.2016.98.
5
Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.新癌症药物的准入时间：从欧盟范围内的营销授权到比利时、爱沙尼亚、苏格兰和瑞典的患者可及性。
Value Health. 2018 Jul;21(7):809-821. doi: 10.1016/j.jval.2018.01.003. Epub 2018 Mar 21.
6
An open science pathway for drug marketing authorization-Registered drug approval.药物上市许可的开放科学途径——已注册药物批准。
PLoS Med. 2021 Aug 9;18(8):e1003726. doi: 10.1371/journal.pmed.1003726. eCollection 2021 Aug.
7
A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU.对美国和欧盟新抗癌药物营销许可申请加速监管审查时间的详细分析。
Clin Transl Sci. 2022 Aug;15(8):1959-1967. doi: 10.1111/cts.13308. Epub 2022 May 31.
8
A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.美国、欧盟和日本基因和细胞治疗药物上市批准十年来的监管决策评估
Cytotherapy. 2018 Jun;20(6):769-778. doi: 10.1016/j.jcyt.2018.03.038. Epub 2018 May 2.
9
A Decade of Marketing Authorization Applications of Anticancer Drugs in the European Union: An Analysis of Procedural Timelines.欧盟抗癌药物上市许可申请的十年：程序时间表分析。
Ther Innov Regul Sci. 2021 Jul;55(4):633-642. doi: 10.1007/s43441-021-00260-5. Epub 2021 Feb 4.
10
EU marketing authorization review of orphan and non-orphan drugs does not differ.欧盟对孤儿药和非孤儿药的上市许可审查并无不同。
Drug Discov Today. 2013 Oct;18(19-20):1001-6. doi: 10.1016/j.drudis.2013.06.012. Epub 2013 Jul 5.
引用本文的文献
1
Viral and non-viral vectors in gene therapy: current state and clinical perspectives.基因治疗中的病毒载体与非病毒载体：现状与临床前景
EBioMedicine. 2025 Jul 1;118:105834. doi: 10.1016/j.ebiom.2025.105834.
2
Contemporary approaches to treat people with hemophilia: what's new and what's not?当代血友病治疗方法：新在哪里，旧在何处？
Res Pract Thromb Haemost. 2025 Jan 31;9(1):102696. doi: 10.1016/j.rpth.2025.102696. eCollection 2025 Jan.
3
Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GENEr8-1 phase III trial.A型血友病基因治疗参与者侵入性操作的结果与管理：GENEr8-1 III期试验的事后分析
Ther Adv Hematol. 2024 Dec 19;15:20406207241304645. doi: 10.1177/20406207241304645. eCollection 2024.
4
The longitudinal kinetics of AAV5 vector integration profiles and evaluation of clonal expansion in mice.AAV5载体整合谱的纵向动力学及小鼠克隆扩增评估
Mol Ther Methods Clin Dev. 2024 Jun 26;32(3):101294. doi: 10.1016/j.omtm.2024.101294. eCollection 2024 Sep 12.
5
Adeno-Associated Virus Engineering and Load Strategy for Tropism Modification, Immune Evasion and Enhanced Transgene Expression.腺相关病毒工程和负载策略用于改变趋向性、免疫逃避和增强转基因表达。
Int J Nanomedicine. 2024 Jul 29;19:7691-7708. doi: 10.2147/IJN.S459905. eCollection 2024.
6
B cell focused transient immune suppression protocol for efficient AAV readministration to the liver.用于向肝脏高效重新给药腺相关病毒的B细胞聚焦短暂免疫抑制方案。
Mol Ther Methods Clin Dev. 2024 Feb 20;32(1):101216. doi: 10.1016/j.omtm.2024.101216. eCollection 2024 Mar 14.
7
Recent advances in various adeno-associated viruses (AAVs) as gene therapy agents in hepatocellular carcinoma.腺相关病毒（AAV）作为基因治疗剂在肝细胞癌中的最新进展。
Virol J. 2024 Jan 12;21(1):17. doi: 10.1186/s12985-024-02286-1.
8
Cellular stress and coagulation factor production: when more is not necessarily better.细胞应激与凝血因子生成：过犹不及。
J Thromb Haemost. 2023 Dec;21(12):3329-3341. doi: 10.1016/j.jtha.2023.10.005. Epub 2023 Oct 14.
9
Modifying immune responses to adeno-associated virus vectors by capsid engineering.通过衣壳工程改变对腺相关病毒载体的免疫反应。
Mol Ther Methods Clin Dev. 2023 Aug 22;30:576-592. doi: 10.1016/j.omtm.2023.08.015. eCollection 2023 Sep 14.
10
State-of-the-art 2023 on gene therapy for phenylketonuria.2023 年基因治疗苯丙酮尿症的最新进展。
J Inherit Metab Dis. 2024 Jan;47(1):80-92. doi: 10.1002/jimd.12651. Epub 2023 Aug 3.
本文引用的文献
1
IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia A mice.IL-15 阻断和雷帕霉素挽救 AAV 转导的血友病 A 小鼠肝细胞中多种因素导致的因子 VIII 丢失。
Mol Ther. 2022 Dec 7;30(12):3552-3569. doi: 10.1016/j.ymthe.2022.07.005. Epub 2022 Jul 12.
2
Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A.腺相关病毒基因治疗血友病 A 后转导 mRNA 和蛋白产生的个体间变异性。
Nat Med. 2022 Apr;28(4):789-797. doi: 10.1038/s41591-022-01751-0. Epub 2022 Apr 11.
3
Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.静脉注射用罗沙帕洛维治疗 A 型血友病的基因疗法。
N Engl J Med. 2022 Mar 17;386(11):1013-1025. doi: 10.1056/NEJMoa2113708.
4
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.血友病 A 的 AAV 基因转移后多年的因子 VIII 表达。
N Engl J Med. 2021 Nov 18;385(21):1961-1973. doi: 10.1056/NEJMoa2104205.
5
Eliminating Panglossian thinking in development of AAV therapeutics.消除腺相关病毒（AAV）疗法开发中的盲目乐观思维。
Mol Ther. 2021 Dec 1;29(12):3325-3327. doi: 10.1016/j.ymthe.2021.10.025. Epub 2021 Nov 10.
6
Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.基因治疗重度 A 型血友病 Valoctocogene roxaparvovec 后止血反应的持久性。
Haemophilia. 2021 Nov;27(6):947-956. doi: 10.1111/hae.14391. Epub 2021 Aug 11.
7
Haemophilia gene therapy: From trailblazer to gamechanger.血友病基因治疗：从开拓者到变革者。
Haemophilia. 2018 May;24 Suppl 6:50-59. doi: 10.1111/hae.13494.
Zotero 插件